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The pneumothorax, and its often invasive treatment, are impressive events in otherwise healthy young patients. The 
relationship between smoking behaviour and the idiopathic spontaneous pneumothorax (ISP) is explained to the 
patients. The objective of the study was to analyse whether smoking behaviour of patients is influenced by the ISP 
(re-) event, and its treatment. Of 145 consecutive ISP patients (1991-1995), 112 were tobacco smokers at time of the 
first ISP. Of the 112, 106 participated in a confidential telephone questionnaire survey combined with retrospective 
medical record analysis. Smoking cessation and reduction percentage related to ISP events, and its treatment, were 
the outcome measurements. 
All patients (mean age 28.8 years at the first ISP) were aware of the relationship between smoking, and ISP at time 
of the first ISP. Age, pack years, and different treatment modalities had no influence on smoking cessation or 
reduction. Some 86.2% of the male and 80.8% of the female patients continued smoking after the first ISP, despite 
the known relationship between smoking, and contracting spontaneous pneumothorax, and despite its often invasive 
treatment. In the group of recurrent pneumothorax events 73.3% continued smoking. 
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Introduction 
Idiopathic spontaneous pneumothorax (ISP) is defined as 
‘air in the pleural space between the parietal and visceral 
pleurae without any predisposing disease’ (1). The air 
results from air leakage from the alveolar space, through 
the interstitium, to the ruptured visceral pleura (2). It is 
hypothesized that alveolar rupture might result from a 
check valve mechanism. Smoking causes peripheral airway 
inflammation, and therefore can cause the check valve (2). 
As shown in literature, ISP is a smoking related disease. Of 
all the Europeans aged 18-30 years in 1993, 33.1% of the 
men and 29.0% of the women smoked cigarettes (3,4). The 
prevalence of smokers among ISP patients is much higher 
(5,6). In a recently reported study from our hospital, 70% of 
the consecutive patients with ISP were smokers (7). ISP is 
typically found in the 2040 year age group, and is less 
frequent in persons over 40 years (7,8). The incidence is 
approximately 0.05% per year (1). 
Patients suffering from an ISP may feel the severe pain of 
pleural irritation, and the dyspnoea caused by the collaps- 
ing lung. The relapse rate is reported as being as high as 
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54% without proper treatment (like, for example, pleuro- 
desis or bullectomy) (9-14). Treatment varies all over the 
world, from minimally invasive to highly invasive proce- 
dures (15). Introduction of a suction drain for several days 
into the chest to remove the air is considered as a minimally 
invasive procedure. This chest tube is often accompanied by 
the sensation of difficult breathing for several days, because 
of pleural irritation. It is considered a rather conservative 
treatment. A far more invasive approach is thoracoscopical 
pleurodesis under local anaesthesia. This is usually very 
painful during and up to 72 h after the procedure. Because 
the patient is usually awake, this may make more of 
an impression than general anaesthesia. If indicated, the 
thoracoscopical video-assisted bullectomy and pleurectomy 
or pleurodesis are performed under general anaesthesia 
usually followed by chest tube drainage, for at least 3 days 
so the patient has also to overcome general anaesthesia. 
The last treatment modality, thoracotomy, is seen as the 
most invasive treatment. 
The experience of the pneumothorax and its subsequent 
treatment, are considered to be impressive events, in these 
relatively young patients. We wondered whether this, 
together with the strong advise of the pulmonologist to stop 
smoking, had any impact on the smoking behaviour of ISP 
patients after first and/or recurrent ISP. 
We studied whether smoking behaviour of ISP patients is 
influenced by the ISP event, its treatment, the ISP re-events, 
as well as some patient characteristics. 
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TABLE 1. Patient characteristics 
Male Female x2 (d.f.) P-value 
All patients 80 26 3.3 (1) 
Only FP 50 11 
RP 30 15 
Age at interview 31.7 
Only FP 31.4 
RP 32.0 
Age at FP 28.8 
Only FP 29.4 
RP 28.0 
Pack years 8.0 
Only FP 9.1 
RP 6.6 
mean SD t-value (d.f) 
7.9 -0.4 (92) 
7.8 
8.2 
7.1 0.9 (88) 
7.3 
8.3 
8.0 1.6 (85) 
14 
8.7 
0.07 
n.s. 
ns. 
n.s. 
Abbreviations: x2 (d.f.), chi-square test (degrees of free- 
dom); ns., not significant; SD, standard deviation; FP, first 
pneumothorax; RP, recurrent pneumothorax. 
Methods 
STUDY DESIGN 
A confidential telephone questionnaire survey combined by 
a retrospective medical record analysis was performed after 
informed consent, on consecutive ISP patients of the Free 
University Hospital Amsterdam. 
SUBJECTS 
Between 1991 and 1995, 142 consecutive ISP patients were 
treated in our hospital. All three patients had the first as 
well as recurrent pneumothoraces treated in our hospital 
between 1985 and 1995. Of these 142 cases, 112 were 
tobacco smokers at the time of the first pneumothorax 
(FP), and were selected for our study. No information was 
obtained from the 30 non-smokers. One hundred and six of 
the 112 patients could be interviewed by telephone by a 
pulmonologist, following their informed consent in the 
same conversation, in September 1996. Exclusion criteria 
for the interview were: incomplete medical records (none), 
hard drugs abuse (one), lung disease at time of the FP 
(none), and age above 55 years (two patients). The age limit 
of 55 years is arbitrarily chosen but reflects the age for ISP 
in literature. The remaining three patients could not be 
reached. All 106 ISP patients agreed to the telephone 
interview. Table 1 summarizes the patient characteristics. 
The 30 non-smokers not interviewed were 26.9 years old at 
time of the FP, 21 were male and nine were female. 
THE INTERVIEW 
Patients were asked to complete questions regarding the 
date of the first pneumothorax and how it had been treated; 
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recurrent pneumothoraces and their treatment; their former 
smoking behaviour (the quantity of cigarettes smoked per 
day at the time of the first pneumothorax); their smoking 
behaviour prior to the event (smoking history in pack 
years), their smoking behaviour 1 yr following the first 
pneumothorax, as well as their current smoking behaviour. 
Non-smokers were asked whether they had permanently 
stopped smoking within 1 yr following the first event or 
after recurrent pneumothoraces. They were asked whether 
they knew, at the time of the first pneumothorax, about the 
strong relationship between smoking and contracting pneu- 
mothoraces, and whether their treating doctor explicitly 
told them about this relationship. 
MEDICAL RECORDS 
There were complete medical records of all 106 patients, 
including surgical reports, lung function parameters [e.g. 
forced expiratory volume in 1 s; (FEV,) and diffusion 
capacity corrected for the alveolar volume (KCO)]. Since 
1985 ISP patient records are used for research purposes and 
are therefore accurately made. Because many patients had 
their first ISP treated in the 1980s there were five treatment 
modalities: (1) bed rest (11 patients) or suction drainage (31 
patients) through the chest tube (at least 3 days in bed); (2) 
pleurodesis with dry talc powder during thoracoscopy 
under local anaesthesia (25 patients, and at least 2 days with 
drain in bed); (3) video-assisted thoracoscopy under general 
anaesthesia (39 patients) with bullectomy (besides general 
anaesthesia, also at least 3 days in bed with the drain) or 
only pleurodesis (at least 2 days in bed with the drain), and 
finally; (4) thoractomy with bullectomy (no patients at time 
of FP, major surgery with a painful scar of weeks). System- 
atical pain scores were not made in the early patient group 
and are therefore not included here. Smoking cessation was 
related to the used treatment, and to RP. 
STATISTICAL PROCEDURES 
Statistical analyses were performed with SPSS for windows 
(version 6.1), including 11’ analyses for categorial variables, 
unpaired f-test for the continuous variables, and logistic 
regression analyses. 
Results 
Table 2 shows the relationship between smoking cessation, 
gender, and treatment modalities. Eighty-two percent of the 
patients had never been treated in a hospital prior to the FP 
event. All of the 106 patients were aware of the relationship 
between smoking and pneumothorax. They all (with one 
exception) confirmed that their treating physician explained 
this at the first pneumothorax event. 
Treatment modalities in the 45 patients with recurrent 
pneumothorax (RP) were compared in relation to smoking 
cessation, Twenty patients had one recurrent pneumo- 
thorax, 17 had two recurrences, three had three recurrences, 
two had four recurrences, two had five, and one had six 
recurrences. 
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TABLE 2. Relationship between smoking behaviour at time of the first pneumothorax, gender, and 
treatment modalities 
Stopped Continued x2 or t-test (d.f.) Continued ~50% 
Age (years) at time FP f SD 29.4 xk 8.1 28.7 i 7.7 0.3 (20)* 27.4 5 6.4 
Pack years f SD 7.5 + 6.3 8.1 f 8.3 - 0.4 (25)” 5.5 i 5.2 
Gender 4.6 (1)” 
Male 11 (13.8%) 69 (86.2%) 15 (18.8%) 
Female 5 (19.2%) 21 (80.8%) 2 (7.7%) 
Treatment+ ’ ., 
Suction drainage or bed rest 
0.62 (2)* 
Thoracoscopi&l talcage (LA) 
5 (11.9%) 37 (88.1%) 9 (21.4%) 
5 (20.0%) 18 (72.0%) 1 (4.0%) 
VATS (GA) 6 (15.4%) 33 (84.6%) 7 (17.9%) 
‘Continued- smoking < 50%’ is included in the group ‘continued’. 
“P-value not significant. 
SD, StandardCdeviation; x2, chi-square; t, unpaired t-test; d.f., degrees of freedom; LA, local 
anaesthesia; VATS (GA), all video-assisted thoracoscopical procedures performed under general 
anaesthesia. ‘I .> 
Of all FP events in the group that later contracted RP, 
the initial treatment existed of drainage or bedrest in 32 
patients, thoracoscopical talc pleurodesis under local 
anaesthesia (LA) in four, video-assisted thoracoscopical 
surgery (VATS) under general anaesthesia (GA) in nine, 
and none had a thoracotomy. Of all RP events, 35 times 
patients received drainage or bedrest, 22 times VATS 
under GA and five times a thoracotomy was performed. In 
the RP group, six (13.3%) patients stopped smoking after 
the FP; four after drainage or bedrest, one after thoraco- 
scopical talc pleurodesis under LA, and one after VATS 
under GA. 
The difference in smoking cessation after the FP, and 
after the RP was significant. The percentage of smokers 
who ceased smoking after the FP in this RP group was the 
same as in the group without RP. Six extra patients (total of 
26.7%) finally stopped smoking after two or more events. 
Compared with smoking cessation after FP in this sub- 
group of 45 this difference is significant (x2=19, d.f.=l, 
P<O.OOOl). Therefore 73.3% continued smoking despite 
recurrences. Twenty percent of the whole RP group 
continued smoking but reduced the amount of cigarettes 
per day by at least 50%. After the FP (in the RP group) 
17.8% continued smoking by ~50% cigarettes per day. The 
invasiveness of the treatment was not of influence here, nor 
was the number of RP. Three patients, who stopped 
smoking after RP, had only suction drains following a 
pneumothorax event, three had pleurodesis under LA, four 
had VATS under GA, and none had a thoractomy. 
A logistic regression analysis was carried out with 
smoking (yes or no 1 yr after the FP) as the dependent 
variable, and gender, age, the treatment modality, and RP 
(ipsilateral or contralateral) as predictor variables. None of 
these predictors significantly contributed to the model, 
which means that none of the variables can give informa- 
tion about the chance, that a smoker, who suffers an ISP 
will stop or continue the smoking behaviour. 
Discussion 
Smoking is known to be a health endangering habit (16- 
20) and smoking cessation lessens this danger (20,21). 
Although in general some people still do not recognize the 
severity of the health risk (22) all 106 young patients were 
aware of this risk to their general health. When asked for, 
all 106 patients knew the relationship between smoking and 
the pneumothorax at the occurrence of the first event. 
Despite these facts, most patients continued smoking. It is 
also seen in other studies, that the awareness of risky 
behaviour does not change the behaviour. In the study 
among 16 000 people aged 18-30 years in 21 European 
countries, with about 33% of the men and 29% of the 
women smoking, the awareness of the link between smok- 
ing and lung cancer and smoking and heart disease was 
uniformly high. Smokers were even more aware of the risks 
than non-smokers in this study (3), though some other 
studies dispute the last remark (22). 
It was said before that the relationship between knowl- 
edge and behaviour is a very weak one (23). The relation- 
ship between attitude and behaviour is stronger. This means 
that it is not enough when the doctor tells the patient he/she 
should stop smoking, and why it is important to do so. It is 
however, strange, that the subjective experience of such a 
potentially life threatening event as an ISP, does not seem 
to change the patients’ attitudes about smoking. A myocar- 
dial infarction can be seen as a similar situation of threat 
for the, mostly older, patients. It is known, that approxi- 
mately 50% of the patients stop smoking after a myocardial 
infarction or coronary bypass grafting at least for some 
time (20,24,25). Perhaps it can be concluded that (1) ISP is 
seen as a less threatening experience than a myocardial 
infarction, or (2) the treatment for ISP is seen as a complete 
cure by the patient. It is very likely that (3) the information 
people receive following a myocardial infarction is more 
directed towards stopping the smoking habit (including 
changing people’s attitudes about smoking) (26), than after 
an ISP event. A similar comparison can be made for 
long-term lung cancer survivors where approximately 50% 
of the patients continued smoking (27,28). 
Females in general show a greater impact of smoking 
related disease on their smoking behaviour than men (29). 
Of the ISP patients we reported, 75.5% are male. Females 
showed a slightly greater (non-significant) tendency 
towards stopping smoking, than the males in our study 
group, which supports these reported findings. Compared 
to lung cancer and myocardial infarction patients, ISP 
patients are younger, and have a shorter smoking history. 
This apparently does not affect the level of addiction. The 
number of pack years smoked before the FP was not 
significantly different in the group who stopped smoking 
compared with the group who continued smoking. 
A critical note has to be made towards the self-reports, 
which were used in this study. Biochemical validation is 
supposed to be more a,ccurate, but was not possible in this 
retrospective study. 4 1992 paper by Velicer et al. shows 
that biochemical validation is not always the ultimate 
mode, because subjects ,nfay refuse biochemical validation 
for reasons unrelated to ‘smoking status (30). They also 
make clear, that as long as self-reports are not used for 
intervention studies, they are accurate enough. Therefore, 
major differences in the results were not to be expected, if 
we had been able to control the self-reports with biochemi- 
cal validation. TSP is a potentially life-threatening event, 
usually seen in people between the ages of 15 and 40 years 
(7,s). Because pain and dyspnoea often accompany a 
pneumothorax, we expected it to be an impressive experi- 
ence for these young patients. Besides the event itself, many 
of the treatment modalities were expected to be impressive 
as well. Many of these ISP patients had never been hospi- 
talized for any treatment before. 
It is difficult to quantify the subjective experience of 
threat, or the ‘impressiveness’ of the pneumothorax and its 
treatment. From clinical experience, it can be confirmed 
that these pneumothorax events are experienced as very 
impressive by the patients. Forty-five patients had one or 
more RP. All of these patients have had more than simply 
a chest tube for treatment, at least once, at the time of 
the interview (this means at least thoracoscopy or 
thoracotomy). At the time of the FP, 13.3% of this RP 
group stopped smoking, and at the time of the interview, 
after one or more recurrences; 26.7% finally stopped, a 
statistically significant difference. The six additional 
patients who stopped smoking were not the ones with more 
pneumothorax events or more invasive treatments, but were 
randomly scattered over the RP group. Nevertheless, only 
six extra patients were convinced enough to stop smoking 
after the recurrences of the pneumothorax. 
In conclusion 84.9% of the smoking patients continued 
smoking after the first idiopathic spontaneous pneumo- 
thorax. Of the men, 18.8% reported to have reduced 
smoking by more than 50%, as did 7.7% of the women. 
In the group with more than one pneumothorax, 73.3% 
continued smoking. Knowledge of the health hazard or 
invasiveness of its treatment does not change the smoking 
behaviour of young spontaneous pneumothorax patients. 
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